Historical Stock Chart
6 Months : From Jun 2019 to Dec 2019
By Michael Dabaie
MyoKardia Inc. (MYOK) now anticipates reporting topline data from the EXPLORER-HCM trial in the second quarter of 2020, ahead of previous guidance of the second half of 2020.
Patient screening has closed for the Phase 3 EXPLORER-HCM study to assess mavacamten in treating patients with obstructive hypertrophic cardiomyopathy. Enrollment into the pivotal trial is expected to be completed by mid-August, MyoKardia said.
MyoKardia also said it re-acquired U.S. royalty rights to mavacamten and MYK-224 from Sanofi S.A. (SNY, SAN.FR). As consideration for the buyback of the U.S. royalty rights to these programs, MyoKardia is paying Sanofi $50 million upfront, with an additional $30 million payable by June 30, 2020.
MyoKardia shares were up 0.4% premarket to $50.00.
Write to Michael Dabaie at email@example.com
(END) Dow Jones Newswires
July 18, 2019 09:14 ET (13:14 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.